The oral contraceptive pill, mechanisms of vascular risk, and practical prescribing strategies for women with thrombotic problems

Women's Vascular Health

Volumn , Issue , 2006, Pages 423-435

  Bloemenkamp, Kitty W M ^a   Helmerhorst, Frans M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 38949089467     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (116)

1. United Nations Department for Economic and Social Information and Policy Analysis Population Division. Levels and Trends of Contraceptive Use as Assessed in 1994. New York: United Nations, 1996.
2. Robinson GE. Lowdose combined oral contraceptives. Br J Obstet Gynaecol 1994; 101: 1036-42.
3. Fotherby K, Caldwell ADS. New progestogens in oral contraception. Contraception 1994; 49: 132.
4. Diczfalusy E. The Contraceptive Revolution: an Era of Scientific and Social Development. Carnforth, UK: Parthenon Publishing, 1997.
5. Oral contraception. In: Speroff L, Fritz MA, Glass RH, Kase NG, eds. Clinical Gynecologic Endocrinology and Infertility, 7th ed. Baltimore: Lipincott, Williams and Wilkins, 2005.
6. Bloemenkamp KWM, Helmerhorst FM, Rosendaal FR, Vandenbroucke JP. Thrombophilias and gynaecology. Best Pract Res Clin Obstet Gynaecol 2003; 17: 509-28.
7. Hannaford P. The collection and interpretation of epidemiological data about the cardiovascular risks associated with the use of steroid contraceptives. Contraception 1998; 57: 137-42.
8. Cardiovascular Disease and Steroid Hormone Contraception. Report of a WHO scientific group. Geneva: World Health Organization, 1998 (WHO Technical Report Series, No. 877).
9. Winkler UH. Effects on hemostatic variables of desogestrel and gestodene-containing oral contraceptives in comparison with levonorgestrel-containing oral contraceptives: a review. Am J Obstet Gynecol 1998; 179: S51-61.
10. Rosing J, Middeldorp S, Curvers J, et al. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomized cross-over study. Lancet 1999; 354: 2036-40.
11. Middeldorp S, Meijers JCM, van den Ende AE, et al. Effects on coagulation of levonorgestrel and desogestrel containing low dose oral contraceptives: a cross-over study. Thromb Haemost 2000; 84: 4-8.
12. Kemmeren JM, Algra A, Meijers JC, et al. Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor V Leiden mutation: a randomized trial. Blood 2004; 103: 927-33.
13. Kemmeren JM, Algra A, Meijers JC, et al. Effects of second and third generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of the factor V Leiden mutation. Thromb Haemost. 2002; 87: 199-205.
14. Tans G, Curvers J, Middeldorp S, et al. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb Haemost. 2000; 84: 15-21.
15. Meijers JCM, Middeldorp S, Tekelenburg W, et al. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent downregulation of fibrinolysis; a randomized cross-over study of two low-dose oral contraceptives. Thromb Haemost 2000; 84: 9-14.
16. Kemmeren JM, Algra A, Meijers JC, et al. Effect of second- and third-generation oral contraceptives on fibrinolysis in the absence or presence of the factor V Leiden mutation. Blood Coagul Fibrinolysis 2002; 13: 373-81.
17. Kierkegaard A. Incidence of acute deep vein thrombosis in two districts. A phlebographic study. Acta Chir Scand 1980; 146: 267-9.
18. Colman RW, Hirsch J, Marder VJ, Salzman EW. Hemostasis and Thrombosis. Basic Principles and Clinical Practice, 3rd edn. Philadelphia: JB Lippincott Company, 1994: 1283-4.
19. Virchow R. Thrombose und embolie. Gefässen entzündung und septische infektion. In: Virchow R, ed. Gesammelte abhandlungen zur wissenschaftlichen Medicin. Frankfurt: Meidinger, Sohn un Co, 1856: 219-732.
20. Lane DA, Mannucci PM, Bauer KA, et al. Inherited thrombophilia: part 1. Thromb Haemost 1996; 76: 651-2.
21. Lane DA, Mannucci PM, Bauer KA, et al. Inherited thrombophilia: part 2. Thromb Haemost 1996; 76: 824-34.
22. Rosendaal FR. Venous thrombosis: a multi-causal disease. Lancet 1999; 353: 1167-73.
23. Vandenbroucke JP, Rosing J, Bloemenkamp KWM, et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med 2001; 344: 1527-35.
24. Kemmeren JM, Algra A, Grobbee DE. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ 2001; 323: 131-4.
25. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995; 346: 1582-8.
26. Jick H, Jick SS, Gurewich V, et al. Risk of idiopathic cardiovascular death and non-fatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346: 1589-93.
27. Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, et al. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995; 346: 1593-6.
28. Spitzer WO, Lewis MA, Heinemann LAJ, et al. on behalf of Transnational Research Group on Oral Contraceptives and the Health of Young women. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. BMJ 1996; 312: 83-8.
29. Farmer RDT, Lawrenson RA, Thompson CR, et al. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet 1997; 349: 83-8.
30. Suissa S, Blais L, Spitzer WO, et al. First-time use of newer oral contraceptives and the risk of venous thromboembolism. Contraception 1997; 56: 141-6.
31. Andersen BS, Olsen J, Nielsen GL, et al. Third-generation oral contraceptives and heritable thrombophilia as risk factors of non-fatal venous thromboembolism. Thromb Haemost 1998; 79: 23-31.
32. Lidegaard Ø, Edström B, Kreiner S. Oral contraceptives and venous thromboembolism. A case-control study. Contraception 1998; 57: 291-301.
33. Lewis MA, MacRae KD, Kühl-Habich D, et al. The differential risk of oral contraceptives: the impact of full exposure history. Hum Reprod 1999; 14: 1493-9.
34. Herings RMC, Urquhart J, Leufkens HGM. Non-causal explanations for the increased risk of venous thromboembolism among users of third-generation oral contraceptives. Pharmacoepidemiol Drug Saf 1996; 5: S1-S119.
35. Herings RMC, Urquhart J, Leufkens HGM. Venous thromboembolism among new users of different oral contraceptives. Lancet 1999; 354: 127-8.
36. Mellemkjaer L, Sørensen HT, Dreyer L, et al. Admission for and mortality from primary venous thromboembolism in women of fertile age in Denmark, 1977-95. BMJ 1999; 319: 820-1.
37. Bloemenkamp KWM, Rosendaal FR, Büller HR, et al. Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias. Arch Intern Med 1999; 159: 65-70.
38. Hennessy S, Berlin JA, Kinman JL, et al. Risk of venous thromboembolism from oral contraceptives containing gestodene and desogestrel versus levonorgestrel: a meta-analysis and formal sensitivity analysis. Contraception 2001; 64: 125-33.
39. Vasilakis-Scaramozza C, Jick H. Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives. Lancet 2001; 358: 1427-9.
40. Heuser P, Tonga K, Hopkins R, et al. Specific oral contraceptive use and venous thromboembolism resulting in hospital admission. N Z Med J 2004; 117: U1176.
41. Seaman HE, de Vries CS, Farmer RD. Venous thromboembolism associated with cyproterone acetate in combination with ethinyloestradiol (Dianette): observational studies using the UK General Practice Research Database. Pharmacoepidemiol Drug Saf 2004; 13: 427-36.
42. Van Grootheest K, Vrieling T. Thromboembolism associated with the new contraceptive Yasmin. BMJ 2003; 326: 257.
43. Heinemann LA, Dinger J. Safety of a new oral contraceptive containing drospirenone. Drug Saf 2004; 27: 1001-18.
44. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A 1993; 90: 1004-8.
45. Bertina RM, Koeleman RPC, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
46. Koster T, Rosendaal FR, Ronde H de, et al. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993; 342: 1503-6.
47. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995; 85: 1504-8.
48. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346: 1133-4.
49. Ridker PM, Miletich JP, Hennekens CH, Buring JE. Ethnic distribution of factor V Leiden in 4047 men and women: implications for venous thromboembolism screening. JAMA 1997; 277: 1305-7.
50. Vandenbroucke JP, Koster T, Briet E, et al. Increased risk of venous thrombosis in oral contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-7.
51. Hellgren M, Svenson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol 1995; 173: 210-13.
52. Heijboer H, Brandjes DPM, Büller HR, et al. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med 1990; 323: 1512-16.
53. Koster T, Rosendaal FR, Briët E, et al. Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study). Blood 1995; 85: 2756-61.
54. Simioni P, Sanson BJ, Prandoni, et al. Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost 1999; 81: 198-202.
55. Pabinger I, Schneider B. Thrombotic risk of women with hereditary antithrombin III, protein C and protein S deficiency taking oral contraceptive medication. The GTH Study Group on Natural Inhibitors. Thromb Haemost 1994; 71: 548-52.
56. Girolami A, Simioni P, Girolami B, Zanardi S. The role of drugs, paticularly oral contraceptives, in triggering thrombosis in congenital defects of coagulation inhibitors: a study of six patients. Blood Coagul Fibrinolysis 1991; 2: 673-8.
57. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3' untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-703.
58. Rosendaal FR, Doggen CJ, Zivelin A, et al. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost 1998; 79: 706-8.
59. Martinelli I, Taioli E, Bucciarelli P, et al. Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis. Arterioscler Thromb Vasc Biol 1999; 19: 700-3.
60. Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects. Arch Intern Med 2000; 160: 49-52.
61. Vessey MP, Doll R. Investigation of relation between use of oral contraceptives and thromboembolic disease. BMJ 1968; 2: 199-205.
62. Koster T, Blann AD, Briet E, et al. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995; 345: 152-5.
63. Kamphuisen PW, Houwing-Duistermaat JJ, van Houwelingen HC, et al. Familial clustering of factor VIII and von Willebrand factor levels. Thromb Haemost 1998; 79: 323-7.
64. Jick H, Slone D, Westerholm B, et al. Venous thrombo-embolic disease and ABO blood type. A cooperative study. Lancet 1969; 1: 539-42.
65. Talbot S, Wakley EJ, Ryrie D, Langman MJ. ABO blood groups and venous thromboembolic disease. Lancet 1970; 1: 1257-9.
66. Bates M. Venous thromboembolic disease and ABO blood type. Lancet 1971; 1: 239.
67. Talbot S, Wakley EJ, Langman MJ. A19 A29 B, and O blood groups, Lewis blood groups, and serum triglyceride and cholesterol concentrations in patients with venous thromboembolic disease. Lancet 1972; 1: 1152-4.
68. Hill H, Loudon NB, Pitcher CS, Pocock VM. Venous thromboembolic disease and ABO blood type. Lancet 1969; I: 623.
69. Mourant AE, Kopec AC, Domaniewska-Sobczak K. Blood groups and blood clotting. Lancet 1971; 1: 223-7.
70. Westerholm B, Wiechel B, Eklund G. Oral contraceptives, venous thromboembolic disease, and ABO blood type. Lancet 1971; Sept 18: 664.
71. Allan TM. ABO blood groups and venous thromboembolism. Lancet 1971; ii: 1209-10.
72. Bloemenkamp KWM, Helmerhorst FM, Rosendaal FR, Vandenbroucke JP. Venous thrombosis, oral contraceptives and high factor VIII levels. Thromb Haemost 1999; 82: 1024-7.
73. Legnani C, Cini M, Cosmi B, et al. Risk of deep vein thrombosis: interaction between oral contraceptives and high factor VIII levels. Haematologica 2004; 89: 1347-51.
74. Bloemenkamp KWM. Oral contraceptives, venous thrombosis and the role of coagulation defects. Academic Thesis, Chapter 10. Venous thrombosis in a monozygotic twin who used oral contraceptives, Leiden, the Netherlands, 1999: 151-5; ISBN 90-9013299-6
75. Kluft C, Lansink M. Effect of oral contraceptives on haemostasis variables. Thromb Haemost 1997; 78: 315-26.
76. Henkens CMA, Bom VJJ, Seinen AJ, Meer van der J. Sensitivity to activated protein C; Influence of oral contraceptives and sex. Thromb Haemost 1995; 73:402-4.
77. Østerud B, Robertsen R, Svang GB, Thijssen F. Resistance to activated protein C is reduced in women using oral contraceptives. Blood Coagul Fibrinolysis 1994; 5: 853-4.
78. Olivieri O, Friso S, Manzato F, et al. Resistance to activated protein C in healthy women taking oral contraceptives. Br J Haematol 1995; 91: 465-70.
79. Bokarewa MI, Falk G, StenLinder M, et al. Thrombotic risk factors and oral contraception. J Lab Clin Med 1995; 126: 294-8.
80. Rosing J, Tans G, Nicolaes GAF, et al. Oral contraceptives and venous thrombosis; different sensitivities to activated protein C in women using second and third-generation oral contraceptives. Br J Haematol 1997; 97: 233-8.
81. Kluft C, de Maat MPM, Heinemann LAJ, et al. Importance of levonorgestrel dose in oral contraceptives for effects on coagulation. Lancet 1999; 354: 832-3.
82. De Visser MCH, Rosendaal FR, Bertina RM. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood 1999; 93: 1271-6.
83. Rodegheiro F, Tosetto A. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism. Ann Intern Med 1999; 130: 643-50.
84. Tans G, van Hylckama Vlieg A, Thomassen MC, et al. Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women. Br J Haematol 2003; 122: 465-70.
85. van Vliet HA, Winkel TA, Noort I, et al. Prothrombotic changes in users of combined oral contraceptives containing drospirenone and cyproterone acetate. J Thromb Haemost 2004; 2: 2060-2.
86. Alhenc-Gelas M, Plu-Bureau G, Guillonneau S, et al. Impact of progestagens on activated protein C (APC) resistance among users of oral contraceptives. J Thromb Haemost 2004; 2: 1594-600.
87. Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, et al. Hemostatic effects of oral contraceptives in women who developed deep-vein thrombosis while using oral contraceptives. Thromb Haemost 1998; 80: 382-7.
88. Consensus Development Meeting. Metabolic aspects of oral contraceptives of relevance for cardiovascular diseases. Am J Obstet Gynecol 1990; 162: 1335-7.
89. Koster T, Rosendaal FR, Reitsma PH, et al. Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms, Leiden Thrombophilia Study. Thromb Haemost 1994; 71: 719-22.
90. Maitra N, Kulier R, Bloemenkamp KW, Helmerhorst FM, Gulmezoglu AM. Progestogens in combined oral contraceptives for contraception. Cochrane Database Syst Rev 2004: CD004861.
91. Badaracco MA, Vessey MP. Recurrence of venous thromboembolic disease and use of oral contraceptives. Br Med J 1974; 1: 215-17.
92. Kyrle PA, Minar E, Bialonczyk C, et al. The risk of recurrent venous thromboembolism in men and women. N Engl J Med 2004; 350: 2558-63.
93. World Health Organization. Improving Access to Quality Care in Family Planning. Medical Eligibility Criteria for Contraceptive Use, 3rd edition WHO 2004. Available at: www.who.int/reproductive-health/publications/mec/mec.pdf
94. Vandenbroucke JP, van der Meer FJ, Helmerhorst FM, Rosendaal FR. Factor V Leiden: should we screen oral contraceptive users and pregnant women? BMJ 1996; 313: 1127-30.
95. Boyce J, Fawcett JW, Noall EWP. Coronary thrombosis and Conovid. Lancet 1963; i: 111.
96. Rosenberg L, Hennekens CH, Rosner B, et al. Oral contraceptive use in relation to nonfatal myocardial infarction. Am J Epidemiol 1980; 111: 59-66.
97. Thorogood M, Mann J, Murphy M, Vessey M. Is oral contraceptive use still associated with an increased risk of fatal myocardial infarction? Report of a case-control study. Br J Obstet Gynaecol 1991; 98: 1245-53.
98. D'Avanzo B, La Vecchia C, Negri E, et al. Oral contraceptive use and risk of myocardial infarction: an Italian case-control study. J Epidemiol Community Health 1994; 48: 324-5.
99. Sidney S, Petitti DB, Quesenberry CP Jr, et al. Myocardial infarction in users of low-dose oral contraceptives. Obstet Gynecol 1996; 88: 939-44.
100. World Health Organization. Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1997; 349: 1202-9.
101. Lewis MA, Heinemann LA, Spitzer WO, et al. The use of oral contraceptives and the occurrence of acute myocardial infarction in young women. Results from the Transnational Study on Oral Contraceptives and the Health of Young Women. Contraception 1997; 56: 129-40.
102. Mant D, Villard-Mackintosh L, Vessey MP, Yeates D. Myocardial infarction and angina pectoris in young women. J Epidemiol Community Health 1987; 41: 215-19.
103. Stampfer MJ, Willett WC, Colditz GA, et al. A prospective study of past use of oral contraceptive agents and risk of cardiovascular diseases. N Engl J Med 1988; 319: 1313-17.
104. Croft P, Hannaford P. Risk factors for acute myocardial infarction in women. BMJ 1989; 298: 674.
105. World Health Organization. Ischaemic stroke and combined oral contraceptives: results of an international, multicentre, case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1996; 348: 498-505.
106. van den Bosch MAAJ, Kemmeren JM, Tanis BC, et al. The RATIO study: oral contraceptives and the risk of peripheral arterial disease in young women. J Thromb Haemost 2003; 1: 439-44.
107. Kemmeren JM, Tanis BC, van den Bosch MA, et al. Risk of Arterial Thrombosis in Relation to Oral Contraceptives (RATIO) study: oral contraceptives and the risk of ischemic stroke. Stroke 2002; 33: 1202-8.
108. Tanis BC, van den Bosch MA, Kemmeren JM, et al. Oral contraceptives and the risk of myocardial infarction. N Engl J Med 2001; 345: 1787-93.
109. Henzl MR, Edwards JA. Pharmacology of progestins. 17-alpha-hydroxyprogesterone derivatives and progestins of the first and second generation. In: Sitruk-Ware R, Mishell DR, eds. Progestins and Antiprogestins in Clinical Practice. New York: Marcel Dekker, 2000: 101-32.
110. Godsland IF, Crook D, Simpson R, et al. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med 1990; 323: 1375-81.
111. Jick H, Jick S, Myers MW, Vasilakis C. Risk of acute myocardial infarction and low-dose combined oral contraceptives. Lancet 1996; 347: 627-8.
112. Dunn N, Thorogood M, Faragher B, et al. Oral contraceptives and myocardial infarction: results of the MICA case-control study. BMJ 1999; 318: 1579-84.
113. Rosendaal FR, van Hylckama Vlieg A, Tanis BC, Helmerhorst FM. Estrogens, progestogens and thrombosis. J Thrombosis Haemost 2003; 1: 1371-80.
114. Kloosterboer HJ, Rekers H. Effects of three combined oral contraceptive preparations containing desogestrel plus ethinyl estradiol on lipid metabolism in comparison with two levonorgestrel preparations. Am J Obstet Gynecol 1990; 163: 370-3.
115. Marz W, Jung-Hoffmann C, Heidt F, et al. Changes in lipid metabolism during 12 months of treatment with two oral contraceptives containing 30 micrograms ethinylestradiol and 75 micrograms gestodene or 150 micrograms desogestrel. Contraception 1990; 41: 245-58.
116. Tanis BC. Lipid levels after long term use of second and third generation oral contraceptives. Thesis, B C Tanis. Arterial thrombosis in young women: role of oral contraceptives and coagulation factors. Thesis Leiden 2003. ISBN: 90-9017251-3.